Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, tox...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Mato, Anthony R., Thompson, Meghan, Allan, John N., Brander, Danielle M., Pagel, John M., Ujjani, Chaitra S., Hill, Brian T., Lamanna, Nicole, Lansigan, Frederick, Jacobs, Ryan, Shadman, Mazyar, Skarbnik, Alan P., Pu, Jeffrey J., Barr, Paul M., Sehgal, Alison R., Cheson, Bruce D., Zent, Clive S., Tuncer, Hande H., Schuster, Stephen J., Pickens, Peter V., Shah, Nirav N., Goy, Andre, Winter, Allison M., Garcia, Christine, Kennard, Kaitlin, Isaac, Krista, Dorsey, Colleen, Gashonia, Lisa M., Singavi, Arun K., Roeker, Lindsey E., Zelenetz, Andrew, Williams, Annalynn, Howlett, Christina, Weissbrot, Hanna, Ali, Naveed, Khajavian, Sirin, Sitlinger, Andrea, Tranchito, Eve, Rhodes, Joanna, Felsenfeld, Joshua, Bailey, Neil, Patel, Bhavisha, Burns, Timothy F., Yacur, Melissa, Malhotra, Mansi, Svoboda, Jakub, Furman, Richard R., Nabhan, Chadi
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6119152/
https://ncbi.nlm.nih.gov/pubmed/29880613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.193615
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados